BRGX (BioRegenx) Moat Score: 1/10 (As of Jul. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is BioRegenx Moat Score?

BioRegenx BRGX Moat Score is 1 as of Jul. 20, 2026. The stock has 5 warning signs investors should review. Among 673 Healthcare Providers & Services companies, BioRegenx ranks better than 75.19% on this metric.

BioRegenx has the Moat Score of 1, which implies that the company might have No Moat - Very weak/transient advantages.

BioRegenx has No Moat: BioRegenx Inc has minimal market presence and lacks significant intellectual property or brand strength. The company does not exhibit durable cost advantages or regulatory barriers, and there is no evidence of strong customer loyalty or network effects.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes BioRegenx might have No Moat - Very weak/transient advantages.

BioRegenx  (OTCPK:BRGX) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

BioRegenx Moat Score Related Terms

BRGX vs VYND, ACON, WLSS: Moat Score Comparison

For the Health Information Services subindustry, BioRegenx's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioRegenx Moat Score vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, BioRegenx's Moat Score distribution charts can be found below:

* The bar in red indicates where BioRegenx's Moat Score falls into.


Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 1 mean?
BioRegenx (BRGX) has a Moat Score of 1 as of Jul. 20, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, BioRegenx ranks #167 out of 673 companies in the Healthcare Providers & Services industry, placing it in the top 24.8%.
Is BioRegenx's Moat Score too high?
BioRegenx's current Moat Score is 1. Based on the distribution chart, BioRegenx ranks #167 out of 673 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers.
How does BioRegenx's Moat Score compare to VYND and ACON?
According to the Healthcare Providers & Services industry distribution chart, BioRegenx ranks #167 out of 673 companies for Moat Score. This places BioRegenx in the top 25% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Healthcare Providers & Services company?
A good Moat Score depends on the Healthcare Providers & Services industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. BioRegenx's current Moat Score is 1. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioRegenx stock overvalued right now?
Based on GuruFocus' analysis, BioRegenx (BRGX) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.01, compared to a current price of $0.01 — trading 24% below its estimated fair value. The current Moat Score is 1. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For BioRegenx (BRGX), the current Moat Score is 1 as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BioRegenx Business Description

Address 7407 Ziegler Road, Chattanooga, TN, USA, 37421
BioRegenx Inc develops and manufactures medical test equipment and high-quality, science-based nutritional products. The Company distributes wellness devices. The products are sold nationally through a direct selling channel to health professionals and research organizations. The company operates and manages its business as one reportable and operating segment as a medical testing, diagnostic and nutraceutical company. It focuses on commercialization of its patented technologies in its field.